Epirubicin may be used in chemotherapy treatment regimens for most types of invasive breast cancer that require chemotherapy, including triple-negative breast cancer. It can also be used with targeted therapy, such as trastuzumab (Herceptin), to treat HER2-positive breast cancers and lower the risk of recurrence.
This medicine can be used in early-stage disease that requires chemotherapy to lower the risk of breast cancer coming back. It can be given either before surgery as neoadjuvant therapy or after surgery as adjuvant treatment.
In metastatic breast cancer, it can be given either alone or with other medicines.
- FEC (5FU, Epirubicin and Cyclophosphamide) or CEF
- EC (Epirubicin and Cyclophosphamide)
Epirubicin is given by vein. It is often given once every 3 weeks for six cycles, or twice (on days one and eight) every 28 days for six cycles.
Common side effects include:
- Decrease of white blood cells, red blood cells and platelets
- Hair loss
- Menopausal symptoms
- Mouth sores
- Nausea and vomiting
- Pain near the site where the medicine was given
Less common side effects include:
Before starting epirubicin, be sure to tell your doctor about any medicines you are taking, including vitamins, herbal supplements and over-the-counter medicines. You should not take epirubicin if you are pregnant.
Share any existing or previous health problems with your doctor, especially if you have a history of heart disease. Your doctor will test you for heart problems before you start treatment and monitor your heart closely during treatment.
There is a slight risk of developing leukemia after taking this medicine, especially when it is given in high doses or together with certain other chemotherapy medicines—talk to your doctor about this risk. Leukemia is cancer of the blood.
Seek immediate medical care if you develop fever, shortness of breath or difficulty breathing, swelling or hives or blistering at the IV site.